INDV vs. CTLT, ELAN, INSM, ROIV, ASND, LEGN, SMMT, CERE, ITCI, and VKTX
Should you be buying Indivior stock or one of its competitors? The main competitors of Indivior include Catalent (CTLT), Elanco Animal Health (ELAN), Insmed (INSM), Roivant Sciences (ROIV), Ascendis Pharma A/S (ASND), Legend Biotech (LEGN), Summit Therapeutics (SMMT), Cerevel Therapeutics (CERE), Intra-Cellular Therapies (ITCI), and Viking Therapeutics (VKTX). These companies are all part of the "pharmaceutical preparations" industry.
Catalent (NYSE:CTLT) and Indivior (NASDAQ:INDV) are both mid-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, media sentiment, institutional ownership, risk, dividends, valuation, earnings and community ranking.
Catalent has a beta of 1.18, suggesting that its share price is 18% more volatile than the S&P 500. Comparatively, Indivior has a beta of 0.63, suggesting that its share price is 37% less volatile than the S&P 500.
Indivior has lower revenue, but higher earnings than Catalent. Catalent is trading at a lower price-to-earnings ratio than Indivior, indicating that it is currently the more affordable of the two stocks.
Catalent received 638 more outperform votes than Indivior when rated by MarketBeat users. However, 100.00% of users gave Indivior an outperform vote while only 59.15% of users gave Catalent an outperform vote.
In the previous week, Catalent had 5 more articles in the media than Indivior. MarketBeat recorded 9 mentions for Catalent and 4 mentions for Indivior. Catalent's average media sentiment score of 1.30 beat Indivior's score of 0.71 indicating that Indivior is being referred to more favorably in the news media.
Catalent presently has a consensus target price of $53.14, suggesting a potential downside of 1.22%. Indivior has a consensus target price of $36.00, suggesting a potential upside of 96.51%. Given Catalent's stronger consensus rating and higher probable upside, analysts plainly believe Indivior is more favorable than Catalent.
Indivior has a net margin of 0.44% compared to Indivior's net margin of -26.61%. Catalent's return on equity of 842.72% beat Indivior's return on equity.
60.3% of Indivior shares are owned by institutional investors. 0.3% of Catalent shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Summary
Indivior beats Catalent on 11 of the 18 factors compared between the two stocks.
Get Indivior News Delivered to You Automatically
Sign up to receive the latest news and ratings for INDV and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding INDV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Indivior Competitors List
Related Companies and Tools
